{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:01:24Z","timestamp":1769151684641,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>SARS-CoV-2 pandemic has posed formidable public health and clinical challenges. The use of immunosuppressive agents, such as high dose corticosteroids and cytokine inhibitors (e.g., Tocilizumab) has been suggested to contrast the hyperinflammatory process involved in the pathogenesis of the severe disease, with conflicting evidence. Among the drawbacks of immunosuppressive therapy, the risk of reactivation of latent infections, including parasitic infestations, is to be considered.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We report a case of a 59-year-old Italian patient treated with high dose intravenous dexamethasone and two intravenous doses of Tocilizumab for interstitial bilateral pneumonia associated with SARS-CoV-2 infection who developed itching, abdominal pain, and an increased eosinophil count. Stool examination confirmed the presence of <jats:italic>S. stercoralis<\/jats:italic> larvae. The patient was treated with a 4-day course of Ivermectin with full recovery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>We report the first case of <jats:italic>S. stercoralis<\/jats:italic> infection following an 11-day treatment with high-dose steroids and Tocilizumab for severe COVID-19. Clinicians should be aware of the risk of strongyloidiasis as a complication of the treatment for severe COVID-19.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-020-01522-4","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T09:47:38Z","timestamp":1599731258000},"page":"539-542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5221-1614","authenticated-orcid":false,"given":"Valentina","family":"Marchese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Crosato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Gulletta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziella","family":"Cristini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Matteelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"1522_CR1","doi-asserted-by":"publisher","first-page":"102433","DOI":"10.1016\/j.jaut.2020.102433","volume":"109","author":"HA Rothan","year":"2020","unstructured":"Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.","journal-title":"J Autoimmun"},{"key":"1522_CR2","doi-asserted-by":"publisher","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","volume":"55","author":"Z Chi","year":"2020","unstructured":"Chi Z, Zhao W, Jia-Wen L, Hong Z, Gui-Qiang W. Cytokine release syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020;55:105954.","journal-title":"Int J Antimicrob Agents."},{"key":"1522_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fmed.2020.00170","volume":"7","author":"N Veronese","year":"2020","unstructured":"Veronese N, Demurtas J, Yang L, Tonelli R, Barbagallo M, Lopalco P, et al. Use of Corticosteroids in coronavirus disease 2019 Pneumonia: a systematic review of the literature. Front Med. 2020;7:170. https:\/\/doi.org\/10.3389\/fmed.2020.00170.","journal-title":"Front Med"},{"key":"1522_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0127-9","author":"W Zhou","year":"2020","unstructured":"Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020. https:\/\/doi.org\/10.1038\/s41392-020-0127-9.","journal-title":"Signal Transduct Target Ther."},{"key":"1522_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0158-2","author":"Y Wang","year":"2020","unstructured":"Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct Target Ther. 2020. https:\/\/doi.org\/10.1038\/s41392-020-0158-2.","journal-title":"Signal Transduct Target Ther."},{"key":"1522_CR6","doi-asserted-by":"publisher","first-page":"104363","DOI":"10.1016\/j.jcv.2020.104363","volume":"127","author":"R Li","year":"2020","unstructured":"Li R, Tian J, Yang F, Lv L, Yu J, Sun G, et al. Clinical characteristics of 225 patients with COVID-19 in a tertiary Hospital near Wuhan. China J Clin Virol. 2020;127:104363. https:\/\/doi.org\/10.1016\/j.jcv.2020.104363.","journal-title":"China J Clin Virol"},{"key":"1522_CR7","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","volume":"180","author":"C Wu","year":"2020","unstructured":"Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan. China JAMA Intern Med. 2020;180:934\u201343. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0994.","journal-title":"China JAMA Intern Med"},{"key":"1522_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2021436","author":"P Horby","year":"2020","unstructured":"Horby P, Wei SL. Dexamethasone in hospitalized patients with Covid-19\u2014preliminary report. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/nejmoa2021436.","journal-title":"N Engl J Med"},{"key":"1522_CR9","doi-asserted-by":"publisher","first-page":"102568","DOI":"10.1016\/j.autrev.2020.102568","volume":"19","author":"P Toniati","year":"2020","unstructured":"Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmunity Rev. 2020;19:102568.","journal-title":"Autoimmunity Rev"},{"key":"1522_CR10","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","volume":"2","author":"G Guaraldi","year":"2020","unstructured":"Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2:e474\u2013e484484.","journal-title":"Lancet Rheumatol"},{"key":"1522_CR11","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24:S21\u201340.","journal-title":"Clin Microbiol Infect"},{"key":"1522_CR12","doi-asserted-by":"publisher","first-page":"f4610","DOI":"10.1136\/bmj.f4610","volume":"347","author":"D Greaves","year":"2013","unstructured":"Greaves D, Coggle S, Pollard C, Aliyu SH, Moore EM. Strongyloides stercoralis infection. BMJ (Online). 2013;347:f4610. https:\/\/doi.org\/10.1136\/bmj.f4610.","journal-title":"BMJ (Online)"},{"key":"1522_CR13","doi-asserted-by":"publisher","first-page":"30310","DOI":"10.2807\/1560-7917.ES.2016.21.31.30310","volume":"21","author":"D Buonfrate","year":"2016","unstructured":"Buonfrate D, Baldissera M, Abrescia F, Bassetti M, Caramaschi G, Giobbia M, et al. Epidemiology of Strongyloides stercoralis in northern Italy: results of a multicentre case\u2013control study, February 2013 to July 2014. Eurosurveillance. 2016;21:30310. https:\/\/doi.org\/10.2807\/1560-7917.ES.2016.21.31.30310.","journal-title":"Eurosurveillance"},{"key":"1522_CR14","unstructured":"WHO | Strongyloidiasis. https:\/\/www.who.int\/intestinal_worms\/epidemiology\/strongyloidiasis\/en\/. Accessed 21 Aug 2020."},{"key":"1522_CR15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/QCO.0b013e3283551dbd","volume":"25","author":"R Mejia","year":"2012","unstructured":"Mejia R, Nutman TB. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis. 2012;25:458\u201363. https:\/\/doi.org\/10.1097\/QCO.0b013e3283551dbd.","journal-title":"Curr Opin Infect Dis"},{"key":"1522_CR16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/1756-185X.12659","volume":"19","author":"C Downey","year":"2016","unstructured":"Downey C. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: a literature review. Int J Rheumatic Dis. 2016;19:536\u201350.","journal-title":"Int J Rheumatic Dis"},{"key":"1522_CR17","first-page":"A5586","volume":"195","author":"TT Mafort","year":"2017","unstructured":"Mafort TT, Reis LVT, Faria LF, Pinto BM, Silva RV, Miranda CS, et al. Alveolar hemorrhage secondary to infection by strongyloides stercoralis in immunosuppressed patient\u2014case report. Am J Respir Crit Care Med. 2017;195:A5586.","journal-title":"Am J Respir Crit Care Med"},{"key":"1522_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-78","author":"D Buonfrate","year":"2013","unstructured":"Buonfrate D, Requena-Mendez A, Angheben A, Mu\u00f1oz J, Gobbi F, Van Den Ende J, et al. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis. 2013. https:\/\/doi.org\/10.1186\/1471-2334-13-78.","journal-title":"BMC Infect Dis."},{"key":"1522_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106103","author":"SH Lan","year":"2020","unstructured":"Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106103.","journal-title":"Int J Antimicrob Agents."},{"key":"1522_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(20)30318-1","author":"H Brotherton","year":"2020","unstructured":"Brotherton H, Usuf E, Nadjm B, Forrest K, Bojang K, Samateh AL, et al. Dexamethasone for COVID-19: data needed from randomised clinical trials in Africa. Lancet Glob Heal. 2020. https:\/\/doi.org\/10.1016\/s2214-109x(20)30318-1.","journal-title":"Lancet Glob Heal"},{"key":"1522_CR21","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/QCO.0b013e32833df718","volume":"23","author":"M Montes","year":"2010","unstructured":"Montes M, Sawhney C, Barros N. Strongyloides stercoralis: there but not seen. Curr Opin Infect Dis. 2010;23:500\u20134.","journal-title":"Curr Opin Infect Dis"},{"key":"1522_CR22","unstructured":"Kassalik M, Moenkemueller K. Strongyloides stercoralis hyperinfection syndrome and disseminated disease. Gastroenterol Epatol. 2011;7."},{"key":"1522_CR23","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/j.1469-0691.2006.01443.x","volume":"12","author":"L Fardet","year":"2006","unstructured":"Fardet L, G\u00e9n\u00e9reau T, Cabane J, Kettaneh A. Severe strongyloidiasis in corticosteroid-treated patients. Clin Microbiol Infect. 2006;12:945\u20137. https:\/\/doi.org\/10.1111\/j.1469-0691.2006.01443.x.","journal-title":"Clin Microbiol Infect"},{"key":"1522_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.4269\/ajtmh.16-0923","volume":"97","author":"A Requena-M\u00e9ndez","year":"2017","unstructured":"Requena-M\u00e9ndez A, Buonfrate D, Gomez-Junyent J, Zammarchi L, Bisoffi Z, Mu\u00f1oz J. Evidence-based guidelines for screening and management of strongyloidiasis in non-endemic countries. Am J Trop Med Hyg. 2017;97:645\u201352.","journal-title":"Am J Trop Med Hyg"},{"key":"1522_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.13170","author":"WM Stauffer","year":"2020","unstructured":"Stauffer WM, Alpern JD, Walker PF. COVID-19 and dexamethasone. A potential strategy to avoid steroid-related strongyloides hyperinfection. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.13170.","journal-title":"JAMA"},{"key":"1522_CR26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1473-3099(19)30289-0","volume":"19","author":"D Buonfrate","year":"2019","unstructured":"Buonfrate D, Salas-Coronas J, Mu\u00f1oz J, Maruri BT, Rodari P, Castelli F, et al. Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial. Lancet Infect Dis. 2019;19:1181\u201390. https:\/\/doi.org\/10.1016\/S1473-3099(19)30289-0.","journal-title":"Lancet Infect Dis"},{"key":"1522_CR27","unstructured":"CDC | Parasites-Strongyloides - Resources for Health Professionals. 2020. https:\/\/www.cdc.gov\/parasites\/strongyloides\/health_professionals\/index.html. Accessed 21 Aug 2020"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-020-01522-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-020-01522-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-020-01522-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T23:34:16Z","timestamp":1631230456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-020-01522-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1522"],"URL":"https:\/\/doi.org\/10.1007\/s15010-020-01522-4","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"28 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors had no financial or other conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from the subject.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}]}}